MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced a significant breakthrough in treating neuropathic pain. A recent pre-clinical study demonstrated that its oral ketamine analog, Ketamir-2, achieved a 100% normalization of pain thresholds in rats at the highest dose. Traditional oral ketamine failed to provide significant relief under the same conditions.

The study, conducted at Pharmaseed Ltd, used a nerve ligation model to mimic human neuropathic pain. Low doses of Ketamir-2 reversed pain for 14 and 22 days post-operation. Higher doses achieved complete normalization of pain thresholds, showing superior efficacy compared to oral ketamine.

MIRA Pharmaceuticals is now conducting additional studies to assess Ketamir-2's effectiveness in treating cancer-induced depression and neuropathic pain. These studies could expedite regulatory approvals and lead to innovative clinical trials. Human efficacy data may be available as early as 2025.

"Developing Ketamir-2 as an oral neuropathic pain treatment marks a significant milestone," said Erez Aminov, CEO of MIRA Pharmaceuticals. Dr. Itzchak Angel, Chief Scientific Advisor, added that Ketamir-2 lacks the severe psychotropic effects of ketamine, positioning it as a promising treatment.